Neonatal Antiepileptic Medication Treatment Patterns: A Decade of Change.
Neonatal Antiepileptic Medication Treatment Patterns: A Decade of Change.
复制标题
DOI：
10.1055/s-0039-1698457
复制
发表时间：
2021-04
影响因子：
2
通讯作者：
Slaughter JL
中科院分区：
文献类型：
--
作者：
Le VT;Abdi HH;Sánchez PJ;Yossef L;Reagan PB;Slaughter LA;Firestine A;Slaughter JL
描述新生儿期开始抗惊厥药物治疗的频率和特征。我们分析了2007年至2016年期间从儿科健康信息系统机构出院的癫痫诊断新生儿队列。通过修改的Poisson回归计算与新生儿（产后≤ 28天）抗惊厥药物开始相关的特征的调整后风险比（aRR）和95%置信区间（CI）。纳入了来自47个机构的6245名婴儿。新生儿期苯巴比妥开始使用率（96.9%至91.3%，P =0.015）和出院时苯巴比妥继续使用率（90.6%至68.6%，P <0.001）均有所下降。新生儿期开始使用左乙拉西坦（7.9%至39.6%，P <0.001）和出院时继续使用左乙拉西坦（9.4%至49.8%，P <0.001）增加。妊娠≥37周出生的新生儿和诊断为脑室内出血、缺血性/血栓性卒中、其他出血性卒中和缺氧缺血性脑病（HIE）的新生儿使用抗惊厥药物的概率较高。最常见的诊断是HIE（n=2223，44.4%）。苯巴比妥仍然是最广泛使用的新生儿癫痫治疗。左乙拉西坦越来越多地用作二线治疗。左乙拉西坦使用的增加表明需要进行额外的研究，以确定其在减少癫痫发作负担和改善长期结局方面的有效性。
To describe the frequency and characteristics of anticonvulsant medication treatments initiated in the neonatal period. We analyzed a cohort of neonates with a seizure diagnosis who were discharged from institutions in the Pediatric Health Information System between 2007 and 2016. Adjusted risk ratios (aRRs) and 95% confidence intervals (CI) for characteristics associated with neonatal (≤ 28-days postnatal) anticonvulsant initiation were calculated via modified Poisson regression. 6245 infants from 47 institutions were included. There was a decrease in both phenobarbital initiation within the neonatal period (96.9% to 91.3%, P =0.015) and continuation at discharge (90.6% to 68.6%, P <0.001). Levetiracetam (7.9% to 39.6%, P <0.001) initiation within the neonatal period and continuation at discharge (9.4% to 49.8%, P <0.001) increased. Neonates born at ≥37-weeks’ gestation and those diagnosed with intraventricular hemorrhage, ischemic/thrombotic stroke, other hemorrhagic stroke, and hypoxic ischemic encephalopathy (HIE) had a higher probability of anticonvulsant administration. The most prevalent diagnosis was HIE (n=2223, 44.4%). Phenobarbital remains the most widely used neonatal seizure treatment. Levetiracetam is increasingly used as a second line therapy. Increasing levetiracetam use indicates a need for additional study to determine its effectiveness in reducing seizure burden and improving long-term outcomes.
登录
查看更多内容
影响因子：
3.6
作者：
Talos DM;Chang M;Kosaras B;Fitzgerald E;Murphy A;Folkerth RD;Jensen FE
通讯作者：
Jensen FE
DOI：
10.1136/archdischild-2015-309639
发表时间：
2017-07
期刊：
Archives of disease in childhood. Fetal and neonatal edition
影响因子：
--
作者：
Martinello K;Hart AR;Yap S;Mitra S;Robertson NJ
通讯作者：
Robertson NJ
影响因子：
2.9
作者：
Maitre, N. L.;Smolinsky, C.;Slaughter, J. C.;Stark, A. R.
通讯作者：
Stark, A. R.
DOI：
10.1136/fn.78.1.f70
发表时间：
1998-01-01
影响因子：
4.4
作者：
Evans, D;Levene, M
通讯作者：
Levene, M
影响因子：
5.1
作者：
Srinivasakumar, Preethi;Zempel, John;Mathur, Amit
通讯作者：
Mathur, Amit